You Searched For "biogen stock" and got 20 results
Sort By:
1 min read
Biogen soars 13% on report of potential acquisition by South Korea's Samsung Group
Biogen could fetch a valuation of more than $42 billion, which would represent at least a 22% premi…
Matthew Fox
2 mins read
Biogen sinks 10% after Medicare limits coverage of new Alzheimer's drug Aduhelm
Medicare seeks to only cover patients who are enrolled in clinical trials evaluating Aduhelm, a dru…
Carla Mozée
1 min read
Biogen tanks 8% after Samsung denies report it was in talks to buy the drugmaker
Samsung's biotech division disputed the report in a filing in South Korea, calling it "not true," a…
Carla Mozée
2 mins read
Biogen falls 8% after 2 major hospital systems say they won't administer controversial Alzheimer's drug
The next big hurdle for Biogen will be receiving approval from health insurers to cover the costs o…
Matthew Fox
1 min read
Biogen jumps 6% ahead of a key FDA decision for its Alzheimer's drug
The second phase 3 trial for Biogen's aducanumab failed to meet its primary and secondary endpoints…
Matthew Fox
2 mins read
Warren Buffett's Berkshire Hathaway sold Biogen, halved its Merck stake, and boosted its Kroger bet. Here's a closer look at its key trades in Q2.
Buffett's company established stakes in Merck, AbbVie, and Bristol Myers Squibb in the second half …
Theron Mohamed
2 mins read
Warren Buffett's Berkshire Hathaway scores $60 million gain on Biogen after FDA approval sends the stock to record high
The famed investor's company saw its Biogen stake soar in value after federal regulators approved t…
Theron Mohamed
1 min read
Biogen plummets 32% after its Alzheimer's therapy fails to win support from FDA advisory committee
The committee voted 8-1 that data from a Biogen study evaluating patients with mild Alzheimer's was…
Matthew Fox
1 min read
Biogen soars 47% after FDA scientists say its Alzheimer's drug's efficacy is 'exceptionally persuasive'
Biogen's drug aducanumab, which was jointly developed with Japan's Eisai, will receive an FDA appro…
Matthew Fox
2 mins read
Biogen soars 43% after its Alzheimer's drug helps slow down cognitive decline in late-stage study
JPMorgan estimates the Alzheimer's drug could generate between $6 billion and $10 billion in peak s…
Matthew Fox
2 mins read
Warren Buffett's Berkshire Hathaway sold its Biogen stake last quarter - and slashed its pharmaceutical bets
The famed investor's company also sold some Chevron and General Motors shares, and boosted its stak…
Theron Mohamed
1 min read
Morgan Stanley double-upgrades Biogen and says the stock can surge another 30%
"While BIIB remains a high-risk/ high-reward stock, we think now is the right time to take the risk…
Carmen Reinicke
2 mins read
US stocks set for muted open after hitting record highs in holiday-thinned trade
Data later Thursday is expected to show a fall in initial jobless claims below 200,000, likely to r…
Shalini Nagarajan
4 mins read
All this AI hype could be distracting us from serious economic threats in the US
Insider's Phil Rosen breaks down the massive Wall Street hype surrounding artificial intelligence a…
Phil Rosen
3 mins read
Medicare sticks by decision to limit coverage of a controversial Alzheimer's drug to people involved in clinical trials
The Medicare coverage decision is a blow for Biogen, which has struggled with sales of its new drug…
Allison DeAngelis
3 mins read
US stocks move lower as investors see hotter inflation and higher rates on the horizon
The S&P 500 lost steam near a record high Monday as investors prepare for consumer price inflation …
Carla Mozée
1 min read
Eli Lilly jumps 10% after it says it will seek approval for its Alzheimer's drug following designation as a breakthrough therapy by the FDA
Goldman Sachs said Eli Lilly's decision to seek accelerated approval for donanemab was ahead of its…
Matthew Fox
2 mins read
US stocks gain to near-record levels as yields fall to 1-month low
US stocks were within striking distance of record highs as inflation fears cool off following a dro…
Matthew Fox
2 mins read
US stocks gain as drop in commodity prices help ease inflation concerns
US stocks moved higher as commodity prices like oil, copper, and lumber continued to move lower fro…
Matthew Fox
1 min read
A $44 billion biotech just got some good news from the FDA about a key Alzheimer's drug, and the stock is soaring
Biogen and Eisai said their experimental Alzheimer's treatment will be reviewed more quickly by reg…